Table 1 Baseline characteristics of participants from the MAGNA VICTORIA study.
Characteristic | Liraglutide (n = 23) | Placebo (n = 26) |
|---|---|---|
Demographics | ||
Age (years) | 59.9 ± 6.2 | 59.2 ± 6.8 |
Sex (n (%)) | ||
Men | 14 (61%) | 15 (58%) |
Women | 9 (39%) | 11 (42%) |
Diabetes duration (years) | 11.3 ± 6.4 | 10.9 ± 7.1 |
Alcohol use (no. (%)) | 9 (39%) | 10 (39%) |
Clinical parameters | ||
Body weight (kg) | 98.4 ± 13.8 | 94.5 ± 13.1 |
BMI (kg/m2) | 32.6 ± 4.4 | 31.6 ± 3.4 |
Total fat mass (%) | 36.1 ± 10.3 | 36.6 ± 8.8 |
Hepatic triglyceride content (%) | 18.1 ± 11.2 | 18.4 ± 9.4 |
Fasting concentrations | ||
CETP (µg/mL) | 0.84 ± 0.22 | 0.81 ± 0.26 |
Total cholesterol (mmol/L) | 4.82 ± 1.02 | 4.80 ± 1.02 |
HDL-cholesterol (mmol/L) | 1.22 ± 0.25 | 1.30 ± 0.39 |
LDL-cholesterol (mmol/L) | 2.60 ± 0.86 | 2.55 ± 0.91 |
Triglycerides (mmol/L) | 2.19 ± 1.51 | 2.10 ± 1.09 |
Glucose (mmol/L) | 8.7 ± 2.7 | 7.3 ± 1.7 |
HbA1c (%) | 8.3 ± 1.1 | 8.1 ± 0.9 |
HbA1c (mmol/mol) | 66.7 ± 11.5 | 64.7 ± 10.2 |
AST (IU/L) | 31 ± 11 | 35 ± 21 |
ALT (IU/L) | 15 ± 7 | 13 ± 5 |
Concomitant drug use | ||
Lipid lowering drugs (no. (%)) | 21 (91%) | 19 (73%) |
Metformin (g/day) | 2.1 ± 0.7 | 2.0 ± 0.5 |
Sulfonylureas (no. (%)) | 6 (26%) | 8 (31%) |
Insulin (no. (%)) | 15 (65%) | 17 (65%) |
Insulin (units) | 70 ± 46 | 69 ± 58 |
